Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain (Q39007494)

8 September 2017

1 reference

title

Investigational drugs targeting the prostaglandin E2 signaling pathway for the treatment of inflammatory pain (English)

1 reference

8 September 2017

1 reference

Sabine Grösch

1

1 reference

8 September 2017

Ellen Niederberger

series ordinal

2

1 reference

8 September 2017

Gerd Geisslinger

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

14 November 2016

1 reference

Expert Opinion on Investigational Drugs

8 September 2017

published in

1 reference

8 September 2017

volume

26

1 reference

8 September 2017

issue

1

1 reference

8 September 2017

page(s)

51-61

1 reference

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Analgesic use and the risk for progression of chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Advances in NSAID development: evolution of diclofenac products using pharmaceutical technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Gastrointestinal safety, chemotherapeutic potential, and classic pharmacological profile of NOSH-naproxen (AVT-219) a dual NO- and H2S-releasing hybrid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Enzymes of the Cyclooxygenase Pathways of Prostanoid Biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostanoids in nociception and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

COX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Central sensitization and LTP: do pain and memory share similar mechanisms?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cellular and Molecular Mechanisms of Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Excitation and sensitization of nociceptors by bradykinin: what do we know?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostaglandin E2 and pain--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Central mechanisms of pathological pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Intrathecal administration of prostaglandin E2 causes sensitization of the primary afferent neuron via the spinal release of glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostanoids and inflammatory pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Peripheral noxious stimulation releases spinal PGE2 during the first phase in the formalin assay of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostacyclin regulates spinal nociceptive processing through cyclic adenosine monophosphate-induced translocation of glutamate receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostacyclin mediates neuropathic pain through interleukin 1β-expressing resident macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

COX-1-dependent prostaglandin D2 in microglia contributes to neuropathic pain via DP2 receptor in spinal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Pharmacodynamic of cyclooxygenase inhibitors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cyclooxygenase inhibitors: From pharmacology to clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Visible small-intestinal mucosal injury in chronic NSAID users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Inhibition of both COX-1 and COX-2 is required for development of gastric damage in response to nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Opposite effects of rofecoxib on nuclear factor-kappaB and activating protein-1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Role of cyclooxygenase isoforms in gastric mucosal defense and ulcer healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Systematic review with network meta-analysis: comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Proton Pump Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Cardiovascular effects of the cyclooxygenase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Lumiracoxib-induced cholestatic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Valdecoxib : the rise and fall of a COX-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

SoluMatrix® Diclofenac: Sustained Opioid-Sparing Effects in a Phase 3 Study in Patients with Postoperative Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

5-Lipoxygenase metabolic contributions to NSAID-induced organ toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Leukotrienes in Nociceptive Pathway and Neuropathic/Inflammatory Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Nitric oxide, aspirin-triggered lipoxins and NO-aspirin in gastric protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Lipoxin and resolvin biosynthesis is dependent on 5-lipoxygenase activating protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

QSAR study of dual cyclooxygenase and 5-lipoxygenase inhibitors 2,6-di-tert-butylphenol derivatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Tetra substituted thiophenes as anti-inflammatory agents: exploitation of analogue-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Synthesis of 4-benzyl-1,3-thiazole derivatives as potential anti-inflammatory agents: an analogue-based drug design approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Licofelone: the answer to unmet needs in osteoarthritis therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Relationship between bone marrow lesions, cartilage loss and pain in knee osteoarthritis: results from a randomised controlled clinical trial using MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Decrease in serum level of matrix metalloproteinases is predictive of the disease-modifying effect of osteoarthritis drugs assessed by quantitative MRI in patients with knee osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Flavocoxid, a nutraceutical approach to blunt inflammatory conditions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Efficacy and safety of flavocoxid compared with naproxen in subjects with osteoarthritis of the knee- a subset analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Hydrogen sulfide in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Hydrogen sulfide-releasing anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Association of phosphatidylcholine and NSAIDs as a novel strategy to reduce gastrointestinal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

COX inhibitors: a patent review (2011 - 2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Membrane prostaglandin E synthase-1: a novel therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Synthesis and pharmacological characterization of benzenesulfonamides as dual species inhibitors of human and murine mPGES-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Structure-activity relationship of nonacidic quinazolinone inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Crystal Structures of mPGES-1 Inhibitor Complexes Form a Basis for the Rational Design of Potent Analgesic and Anti-Inflammatory Therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Insights into the structure activity relationship of mPGES-1 inhibitors: Hints for better inhibitor design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Pharmacodynamic comparison of LY3023703, a novel microsomal prostaglandin e synthase 1 inhibitor, with celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

PGE2/EP4 signaling in peripheral immune cells promotes development of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Novel prostaglandin receptor modulators--part II: EP receptor modulators; a patent review (2002 - 2012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

A Prospective, Randomized, Masked, Placebo-Controlled Multisite Clinical Study of Grapiprant, an EP4 Prostaglandin Receptor Antagonist (PRA), in Dogs with Osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Discovery of potent aryl-substituted 3-[(3-methylpyridine-2-carbonyl) amino]-2,4-dimethyl-benzoic acid EP4 antagonists with improved pharmacokinetic profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Discovery of 4-[1-[([1-[4-(trifluoromethyl)benzyl]-1H-indol-7-yl]carbonyl)amino]cyclopropyl]benzoic acid (MF-766), a highly potent and selective EP4 antagonist for treating inflammatory pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Small molecules with anti-inflammatory properties in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Nonsteroidal antiinflammatory drugs: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

In Vitro Generation of Functional Liver Organoid-Like Structures Using Adult Human Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

A first vascularized skin equivalent as an alternative to animal experimentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

Long-Term Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drug Use According to Time Passed After First-Time Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/13543784.2017.1260544

10.1080/13543784.2017.1260544

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference